Morgan Stanley maintains a "overweight" rating on GUSHENGTANG(02273) with a target price of 62 Hong Kong dollars.
Currently, private hospitals are not required to participate in volume-based procurement. The company expects the group to achieve a revenue growth of over 20% this year, with a profit increase of over 25%.
Morgan Stanley released a research report stating that they are maintaining a "buy" rating for GUSHENGTANG (02273) with a target price of 62 Hong Kong dollars. Currently, private hospitals are not required to participate in volume-based procurement. The bank expects the group to achieve revenue growth of over 20% this year, with profit growth expected to be over 25%.
Related Articles
US Stock Market Move | Partial encryption mining concept stocks fluctuate and rise, TeraWulf (WULF.US) rises nearly 5%.
US Stock Market Move | Fujian Eastern Red (ORIS.US) Soars Over 25% and Plans to Acquire Controlling Stake in Hubei Daguan Tea Industry Group.
US Stock Market Move | New antiemetic drug Nereus approved by FDA, Vanda Pharmaceuticals Inc. (VNDA.US) surges over 32%
US Stock Market Move | Partial encryption mining concept stocks fluctuate and rise, TeraWulf (WULF.US) rises nearly 5%.
US Stock Market Move | Fujian Eastern Red (ORIS.US) Soars Over 25% and Plans to Acquire Controlling Stake in Hubei Daguan Tea Industry Group.
US Stock Market Move | New antiemetic drug Nereus approved by FDA, Vanda Pharmaceuticals Inc. (VNDA.US) surges over 32%
